Thermo Fisher Launches Next-Gen AI-Powered Orbitrap Mass Spectrometers

Thermo Fisher Scientific (NYSE: TMO) unveiled two new mass spectrometers at the American Society for Mass Spectrometry (ASMS) Conference in late May 2026: the Thermo Scientific Orbitrap Tribrid Apex and Orbitrap Excedion. These instruments combine high sensitivity and speed with AI-enabled software and the Olink proteomics platform, aiming to streamline drug discovery and development.

The Product

The Orbitrap Tribrid Apex offers unprecedented accuracy in multiomics analysis, while the Orbitrap Excedion focuses on rapid analysis of complex drug compounds. Both are equipped with AI software that improves result accuracy and reduces analysis time, and integrate with the Olink platform for large-scale proteomics.

Pricing and Availability

Pricing has not been disclosed yet. The instruments are expected to be available for order in Q3 2026, with initial shipments planned by year-end.

Competition

Thermo Fisher faces competition from Agilent Technologies, Bruker, and Waters Corporation, which also offer advanced mass spectrometers. However, the focus on AI and Olink may give TMO a competitive edge in the fast-growing proteomics market.

Potential Impact on the Company

These launches are expected to strengthen Thermo Fisher's position in the life sciences tools market, valued at over $50 billion. Integrating AI aligns with industry trends toward automation and intelligent analysis, potentially boosting market share and revenue in drug discovery.